natgillin/translations-raw huggingface dataset:
Excipients: Sodium citrate, glycine, trehalose dihydrate, mannitol, polysorbate 80 and water for injections. 
Pomoćne tvari: natrijev citrat, glicin, trehaloza dihidrat, manitol, polisorbat 80 i voda za injekcije.
PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 powder vial, 1 vial with solvent (5 mL), 1 Mix2Vial device 
OBLIK I SADRŽAJ Prašak i otapalo za otopinu za injekciju Sadržaj: 1 bočica s praškom, 1 bočica s otapalom (5 ml), 1 Mix2Vial uređaj
VEYVONDI 650 IU powder and solvent for solution for injection Each vial of powder contains nominally 650 International Units (IU) vonicog alfa. 
VEYVONDI 650 IU prašak i otapalo za otopinu za injekciju Jedna bočica praška nominalno sadrži 650 međunarodnih jedinica (IU) vonikoga alfa.
VEYVONDI contains the active substance vonicog alfa, which is a recombinant human von Willebrand factor (rVWF). 
VEYVONDI sadrži djelatnu tvar vonikog alfa, a to je rekombinantni ljudski von Willebrandov faktor (rVWF).
5 To connect the solvent vial to the VEYVONDI vial, turn the solvent vial over and place it on top of the vial containing VEYVONDI concentrate. 
Da biste spojili bočicu otapala na bočicu s lijekom VEYVONDI, okrenite bočicu otapala i postavite je na vrh bočice koja sadrži VEYVONDI koncentrat.
Inspect the syringe visually for particulate matter; the solution should be clear and colourless. 
Štrcaljku treba pregledati kako biste provjerili sadrži li strane čestice; otopina treba biti bistra i bezbojna.
Table 2 VWF:RCo and FVIII:C Target Levels Recommended Target Peak Plasma Levels of VWF:RCo and FVIII:C be Achieved Prior to Surgery for the Prevention of Excessive Bleeding During and After Surgery 
Tablica 2: Ciljne razine VWF:RCo i FVIII:C Preporučene ciljne vršne plazmatske razine VWF:RCo i FVIII:C koje treba postići prije kirurškog zahvata za sprečavanje prekomjernog krvarenja tijekom i nakon kirurškog zahvata
PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Contents: 1 powder vial , 1 vial with solvent (10ml), 1 Mix2Vial device 
OBLIK I SADRŽAJ Prašak i otapalo za otopinu za injekciju Sadržaj: 1 bočica s praškom, 1 bočica s otapalom (10 ml),, 1 Mix2Vial uređaj
9 Leaving the VEYVONDI vial (containing the reconsituted product) on your flat work surface, connect the syringe to the clear plastic connector and turning the syringe clockwise. 
9 Bočicu s lijekom VEYVONDI (koja sadrži rekonstituirani lijek) ostavite na ravnoj radnoj površini, a štrcaljku spojite na prozirni plastični priključak i okrenite štrcaljku u smjeru kazaljke na satu.
Vonicog alfa is a purified recombinant human von Willebrand factor (rVWF). 
Vonikog alfa je pročišćen rekombinantni ljudski von Willebrandov faktor (rVWF).
Inhibitors (antibodies) against the VWF may occur in some patients receiving the medicine.These inhibitors, especially at high levels, could cause the treatment to stop working properly. 
Inhibitori (antitijela) koji djeluju protiv VWF-a mogu se javiti u nekih bolesnika koji primaju lijek.
NAME OF THE MEDICINAL PRODUCT VEYVONDI 1300 IU powder and solvent for solution for injection vonicog alfa (recombinant human von Willebrand factor) 
VEYVONDI 1300 IU prašak i otapalo za otopinu za injekciju vonikog alfa (rekombinantni ljudski von Willebrandov faktor)
Always use this medicine exactly as your doctor has told you. 
Ako primijenite više lijeka VEYVONDI nego što ste trebali Uvijek primijenite ovaj lijek točno onako kako Vam je rekao liječnik.
NAME OF THE MEDICINAL PRODUCT VEYVONDI 650 IU powder and solvent for solution for injection vonicog alfa (recombinant human von Willebrand factor) 
VEYVONDI 650 IU prašak i otapalo za otopinu za injekciju vonikog alfa (rekombinantni ljudski von Willebrandov faktor)
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS SOLVENT VIAL LABEL (5mL) 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA NA BOČICI S OTAPALOM (5 ml)
Cardiac disorders 
Srčani poremećaji Tahikardija
5 To connect the solvent vial to the VEYVONDI vial, turn the solvent vial over and place it on top of the vial containing VEYVONDI powder. 
Da biste spojili bočicu otapala na bočicu s lijekom VEYVONDI, okrenite bočicu otapala i postavite je na vrh bočice koja sadrži VEYVONDI prašak.
If the FVIII:C levels are not at the recommended target levels, rFVIII should be administered in addition to vonicog alfa to raise VWF:RCo and FVIII:C. Please refer to (Table 2) for FVIII:C recommended target levels. 
Ako razine FVIII:C nisu pri preporučenim ciljnim razinama, rFVIII treba primijeniti kao dodatak vonikogu alfa kako bi se povisile razine VWF:RCo i FVIII:C.
Check the expiry date, and ensure that the VEYVONDI powder and water for injections (solvent) are at room temperature prior to preparation. 
Provjerite rok valjanosti i osigurajte da su VEYVONDI prašak i voda za injekciju (otapalo) na sobnoj temperaturi prije pripreme.
Table 3 Recommended Target Trough Plasma Levels of VWF:RCo and FVIII:C and Minimum Duration of Treatment for Subsequent Maintenance Doses for the Prevention of Excessive Bleeding During and After Surgery 
Tablica 3: Preporučene najniže ciljne razine VWF:RCo i FVIII:C u plazmi i minimalno trajanje liječenja za naknadne doze održavanja za prevenciju prekomjernog krvarenja nakon kirurškog zahvata
VEYVONDI 650 IU powder and solvent for solution for injection Each pack contains: - powder in a vial (type I glass), with a butyl rubber stopper - 5 mL of solvent in a vial (type I glass), with a rubber stopper (chlorobutyl) - one reconstitution device (Mix2Vial) 
VEYVONDI 650 IU prašak i otapalo za otopinu za injekciju Jedno pakiranje sadrži: - prašak u bočici (staklo tip I), s čepom od butilne gume - 5 ml otapala u bočici (staklo tipa I), s gumenim čepom (klorobutil) - jedan uređaj za rekonstituciju (Mix2Vial)
0.80 - 1 IU/mL Δ 
0,80 - 1 IU/ml b
FVIII:C Target Peak Plasma 
FVIII:C Ciljna najniža razina u plazmi
FVIII:C Target Peak Plasma Level a 
Ciljna vršna razina FVIII:C u plazmi a
The solvent will flow into the VEYVONDI vial by vacuum. 
Otapalo će se pomoću vakuuma uliti u bočicu s lijekom VEYVONDI.
Table 2 Recommended Target Peak Plasma Levels of VWF:RCo and FVIII:C to be Achieved Prior to Surgery for the Prevention of Excessive Bleeding During and After Surgery 
Tablica 2: Preporučene ciljne vršne, plazmatske razine VWF:RCo i FVIII:C koje treba postići prije kirurškog zahvata za sprečavanje prekomjernog krvarenja tijekom i nakon kirurškog zahvata
Each pack of VEYVONDI 650 IU contains: - powder in a glass vial with a rubber stopper - 5 mL of solvent in a glass vial with a rubber stopper - one reconstitution device (Mix2Vial) 
Jedno pakiranje lijeka VEYVONDI 650 IU sadrži: - prašak u staklenoj bočici s gumenim čepom - 5 ml otapala u staklenoj bočici s gumenim čepom - jedan uređaj za rekonstituciju (Mix2Vial)
Each pack of VEYVONDI 1300 IU contains: - powder in a vial (type I glass), with a butyl rubber stopper - 10 mL of solvent in a vial (type I glass), with a rubber stopper (bromobutyl) - one reconstitution device (Mix2Vial) 
Jedno pakiranje lijeka VEYVONDI 1300 IU sadrži: - prašak u bočici (staklo tip I), s čepom od butilne gume - 10 ml otapala u staklenoj bočici (staklo tip I), s gumenim čepom (bromobutil) - jedan uređaj za rekonstituciju (Mix2Vial)
MedDRA System Organ Class (SOC) 
MedDRA klasifikacija organskih sustava
NAME OF THE MEDICINAL PRODUCT VEYVONDI 650 IU powder and solvent for solution for injection. 
VEYVONDI 650 IU prašak i otapalo za otopinu za injekciju.
Ensure that the VEYVONDI powder vial and the Sterilised Water for Injections (solvent) are at room temperature prior to preparation. 
Bočica s praškom VEYVONDI i sterilizirana voda za injekcije (otapalo) moraju biti na sobnoj temperaturi prije pripreme.
Investigations 
(Ispitivanje
Immunogenicity 
Hipertenzija
- Ensure that the VEYVONDI powder vial and the sterilised water for injections (solvent) are at room temperature prior to preparation. 
- Bočica s praškom VEYVONDI i sterilizirana voda za injekcije (otapalo) moraju biti na sobnoj temperaturi prije pripreme.
Adverse Reaction by Preferred Term (PT) 
Nuspojava po preporučenom pojmu
Phase 3 PK50 VEYVONDI (Study 071001) 
PK50 Faze 3 VEYVONDI (Ispitivanje
Clinical and compatibility studies were conducted to administer vonicog alfa (human von Willebrand factor) with octocog alfa (human coagulation factor) in the same syringe. 
Provedena su klinička ispitivanja i ispitivanja kompatibilnosti za primjenu vonikoga alfa (ljudskog von Willebrandovog faktora) s oktokogom alfa (ljudskim koagulacijskim faktorom) u istoj štrcaljki. rVWF i rFVIII mogu se prethodno pomiješati u istoj štrcaljki kako bi se dobila odgovarajuća doza (vidjeti dio 4.2 za način primjene).
Δ = Target peak plasma VWF:RCo - baseline plasma VWF:RCo cIR = Incremental Recovery as measured in the subject. 
= Ciljna vršna razina VWF:RCo u plazmi - početna razina VWF:RCo u plazmi IR = prirast po jedinici doze (engl.
Excipients: Sodium citrate, glycine, trehalose dihydrate, mannitol, polysorbate 80, and water for injections. 
Pomoćne tvari: natrijev citrat, glicin, trehaloza dihidrat, manitol, polisorbat 80 te voda za injekcije, Vidjeti uputu o lijeku za više informacija.
After reconstitution with the 5 mL solvent provided, VEYVONDI contains approximately 130 IU/mL vonicog alfa. 
Nakon rekonstitucije s 5 ml priloženog otapala, VEYVONDI sadrži približno 130 IU/mL vonikoga alfa.
After reconstitution with the 10 mL solvent provided, VEYVONDI contains approximately 130 IU/mL vonicog alfa. 
Nakon rekonstitucije s 10 ml priloženog otapala, VEYVONDI sadrži približno 130 IU/mL vonikoga alfa.
1 vial contains 650 IU vonicog alfa, approx. 130 IU/mL after reconstitution with 5 mL water for Injections 
1 bočica sadrži 650 IU vonikoga alfa, otprilike 130 IU/ml nakon rekonstitucije s 5 ml vode za injekcije Specifična aktivnost: približno 110 IU VWF:RCo/mg proteina
IV 
Δ
Vertigo 
Trombogenost
There is a risk of occurrence of thrombotic events if you have known clinical or laboratory risk factors.Therefore your doctor will monitor you for early signs of thrombosis. 
Postoji opasnost od pojave trombotskih događaja ako imate poznate kliničke ili laboratorijske čimbenike rizika.
Shaking will adversely affect the product. 
Trešnja štetno djeluje na lijek.
Phase 3 PK80 
PK80 faze 3 VEYVONDI (Ispitivanje
Pruritus generalized 
Prijavljivanje nuspojava
Haemorrhage 
Vrtoglavica
VEYVONDI 1300 IU powder and solvent for solution for injection Each pack contains: - powder in a vial (type I glass), with a butyl rubber stopper 
VEYVONDI 1300 IU prašak i otapalo za otopinu za injekciju Jedno pakiranje sadrži: - prašak u bočici (staklo tip I), s čepom od butilne gume - 10 ml otapala u bočici (staklo tip I), s gumenim čepom (bromobutil) - jedan uređaj za rekonstituciju (Mix2Vial)
Tachycardia 
Omaglica
Prevention of bleeding/haemorrhage and treatment in case of elective surgery Assess FVIII:C levels prior to initiation of any surgical procedure. 
Procijenite razine FVIII:C prije započinjanja bilo kojeg kirurškog zahvata.
How VEYVONDI is given 
Što VEYVONDI sadrži
Gastrointestinal disorders 
Duboka venska tromboza
Side effects are similar in children. 
Nuspojave su slične i u djece.
This summary was last updated in 11-2013. 
Sažetak je posljednji put ažuriran u 11.2013.
The vaccine would be given according to official recommendations. 
Cjepivo se treba primjenjivati u skladu sa službenim preporukama.
This is a special type of vaccine that is designed to help with the management of a future pandemic. 
Ovo je poseban tip cjepiva koji je dizajniran kao pomoć pri upravljanju budućim pandemijama.
It contains influenza (flu) viruses that have been inactivated (killed). 
Sadrži viruse influence (gripe) koji su inaktivirani (ubijeni).
One main study in adults included 561 healthy volunteers, 281 of whom were over the age of 60 years. 
Jedno glavno ispitivanje provedeno u odraslih bolesnika obuhvatilo je 561 zdravog dobrovoljca, od kojih je 281 dobrovoljac bio stariji od 60 godina.
It should only be used once a flu pandemic has been officially declared by the World Health Organization or European Union (EU). 
Treba se koristiti tek nakon što Svjetska zdravstvena organizacija ili Europska unija (EU) službeno proglasi pandemiju gripe.
The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again. 
Imunološki sustav može zatim brže proizvoditi protutijela nakon što je ponovno izložen virusu.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease. 
Cjepiva djeluju „učeći” imunološki sustav (prirodnu obranu tijela) kako da se brani protiv bolesti.
Every year, the European Medicines Agency (EMA) will review any new information that may become available and this summary will be updated as necessary. 
Svake godine Europska agencija za lijekove procjenjuje sve nove dostupne informacije te se ovaj sažetak po potrebi ažurira.
The vaccine contains a flu strain called A/VietNam/1203/2004 (H5N1). 
Cjepivo sadrži soj gripe naziva A/VietNam/1203/2004 (H5N1).
Before a pandemic starts, nobody knows which strain of flu virus will be involved, so pharmaceutical companies cannot prepare the correct vaccine in advance. 
Prije početka pandemije nitko ne zna koji soj virusa će biti uključen u cjepivo, tako da farmaceutske tvrtke ne mogu unaprijed pripremiti ispravno cjepivo.
The study also looked at the effect of a booster dose given after twelve months in some of the children. 
Ispitivanje je također istražilo djelovanje dodatne doze primijenjene nakon dvanaest mjeseci u pojedine djece.
The vaccine must not be given to people who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any of the substances found at trace (very low) levels in the vaccine, such as formaldehyde, benzonase or sucrose. 
Cjepivo se ne smije primjenjivati u osoba koje imaju anafilaktičku reakciju (ozbiljnu alergijsku reakciju) na bilo koju komponentu cjepiva ili na bilo koju pomoćnu tvar koja je prisutna u tragovima (vrlo malo) u cjepivu, poput formaldehida, benzonasa ili sukroze.
This helps to protect against the disease. 
Ovo može pomoći pri zaštiti od bolesti uzrokovanom virusom.
Instead, they can prepare a vaccine that contains a strain of flu virus specifically chosen because nobody has been exposed to it, and to which nobody is immune. 
Umjesto toga mogu pripremiti cjepivo koje sadrži soj virusa gripe koji je posebno odabran zato što niti jedna osoba nije izložena tom soju, i nitko nije imun na njega.
According to criteria laid down by the Committee for Medicinal Products for Human Use (CHMP), a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of adults for it to be considered suitable. 
Sukladno kriterijima utvrđenima od strane Povjerenstva za lijekove za primjenu kod ljudi (CHMP), „mock-up” cjepivo mora stvoriti zaštitne razine protutijela u najmanje 70% odraslih bolesnika da bi se smatralo primjerenim.
They can then test this vaccine to see how people react to it, allowing them to predict how people will react when the flu strain causing the pandemic is included. 
Farmaceutske tvrtke mogu samo testirati ovo cjepivo i vidjeti kako osobe reagiraju na njega, što im omogućuje da predvide kako će osobe reagirati nakon što se soj gripe koji uzrokuje pandemiju uključi u cjepivo.
Although levels of antibodies slowly fell over the year after vaccination, a booster dose after 12 months resulted in protective levels of antibodies in 93 to 100% of children who received it. 
Iako su se razine protutijela snižavale tijekom godine nakon cijepljenja, dodatna doza nakon 12 mjeseci rezultirala je zaštitnim razinama protutijela u 93 do 100% djece koja su primila cjepivo.
This vaccine is the same as the Celvapan H5N1 mock-up vaccine, which was previously authorised in the European Union (EU). 
Ovo cjepivo je isto kao „mock-up” cjepivo Celvapan H5N1 koje je prethodno odobreno u Europskoj uniji (EU).
whole virion influenza virus, propagated in vero cells (continuous cell line of mammalian origin), inactivated, containing antigen of pandemic strain 
cijeli virion virusa influence, pripremljeno u staničnoj kulturi (kontinuirana stanična linija porijekla sisavaca), inaktivirano, sadrži antigen pandemijskog soja
When a person is given the vaccine, the immune system recognises the inactivated virus as ‘foreign' and makes antibodies against it. 
Nakon što osoba primi cjepivo, imunološki sustav prepoznaje virusni dio kao „strano” tijelo i stvara protutijela protiv njega.
At 21 days after the second injection, 72% of the adults below 60 years of age (192 out of 265) and 74% of those above 60 years of age (200 out of 270) had levels of antibodies that would protect them against H5N1. 
U 21. danu nakon druge injekcije, 72% odraslih osoba mlađih od 60 godina (192 od 265) i 74% odraslih bolesnika starijih od 60 godina (200 od 270) imalo je razine protutijela koje bi ih zaštitile od H5N1.
The main measure of effectiveness was the production of protective levels of antibodies 21 days after the second vaccination. 
Glavna mjera djelotvornosti bilo je stvaranje zaštitnih razina protutijela 21. dan nakon drugog cijepljenja.
The full EPAR for Pandemic Influenza Vaccine H5N1 Baxter AG can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o cjepivu protiv pandemijske influence H5N1 Baxter AG nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A flu pandemic happens when a new type (strain) of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world. 
Pandemija gripe nastupa nakon što se pojavi novi tip (soj) virusa gripe koji se može lako proširiti s osobe na osobu zato što ljudi nemaju imunitet (zaštitu) protiv tog soja.
The second main study involved 305 children aged 9 to 17 years, 306 aged 3 to 8 years and 73 aged 6 to 35 months, and also examined the effect of two 7.5 microgram doses of the vaccine 21 days apart. 
Drugim glavnim ispitivanjem obuhvaćeno je 305 djece u dobi od 9 do 17 godina, 306 u dobi od 3 do 8 godina i 73 u dobi od 6 do 35 mjeseci, te je također ispitano djelovanje dvije doze cjepiva od 7,5 mikrograma, primijenjene u razmaku od 21 dana.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pandemic Influenza Vaccine H5N1 Baxter AG. 
Objašnjava kako je Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) ocijenilo lijek da bi donijelo svoje mišljenje u korist davanja odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima za primjenu cjepiva protiv pandemijske influence H5N1 Baxter AG.
Similarly in children, after the second 7.5-microgram dose, 85% of children aged 9 to 17 years, 73% of those 3 to 8 years, and 69% of those aged 6 to 35 months had protective levels of antibodies 21 days after the second injection. 
Slično je bilo i u djece, nakon druge doze od 7,5 mikrograma, 85% djece u dobi od 9 do 17 godina, 73% djece u dobi od 3 do 8 godina i 69% u dobi od 6 do 35 godina imalo je zaštitne razine protutijela 21. dan nakon druge injekcije.
The most common side effects with Pandemic Influenza Vaccine H5N1 Baxter AG in adults (seen in more than 1 person in 10) are headache, fatigue (tiredness) and pain at the site of the injection. 
Najčešće nuspojave cjepiva protiv pandemijske influence H5N1 Baxter AG u odraslih bolesnika (kod više od 1 na 10 osoba) su glavobolja, iscrpljenost (umor) i bol u mjestu injekcije.
When the company that makes Pandemic Influenza Vaccine H5N1 Baxter AG includes the flu strain responsible for a pandemic in the vaccine, it will collect information on the safety and effectiveness of the final pandemic vaccine, and submit this to the CHMP for evaluation. 
Nakon što proizvođač cjepiva protiv pandemijske influence H5N1 Baxter AG uključi soj gripe odgovoran za pandemiju u cjepivo, prikupit će informacije o sigurnosnoj primjeni i djelotvornosti konačnog cjepiva protiv pandemije te će dostaviti ove podatke CHMP-u na procjenu.
For more information about treatment with Pandemic Influenza Vaccine H5N1 Baxter AG, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji cjepivom protiv pandemijske influence H5N1 Baxter AG pročitajte u uputama o lijeku (također dio EPAR-a) odnosno obratite se svom liječniku ili ljekarniku.
Pandemic Influenza Vaccine H5N1 Baxter AG is given by injection into the shoulder muscle or thigh in two doses, at least three weeks apart. 
Cjepivo protiv pandemijske influence H5N1 Baxter AG primjenjuje se injekcijom u deltoidni mišić ili bedro u dvije doze, u razmaku od najmanje tri tjedna.
The company that made the Celvapan H5N1 mock-up vaccine has agreed that its scientific data can be used for Pandemic Influenza Vaccine H5N1 Baxter AG (‘informed consent'). 
Proizvođač „mock-up” cjepiva Celvapan H5N1 je pristao da se njegovi znanstveni podaci koriste za cjepivo protiv pandemijske influence H5N1 Baxter AG („informirani pristanak”).
The European Commission granted a marketing authorisation valid throughout the European Union for Pandemic Influenza Vaccine H5N1 Baxter AG on 16 October 2009. 
Europska komisija izdala je odobrenje za stavljanje u promet koje za cjepivo protiv pandemijske influence H5N1 Baxter AG vrijedi na prostoru Europske unije od 16. listopada 2009.
The CHMP decided that Pandemic Influenza Vaccine H5N1 Baxter AG's benefits are greater than its risks in all age groups investigated and recommended that it be given marketing authorisation. 
CHMP je odlučio da koristi od cjepiva protiv pandemijske influence H5N1 Baxter AG nadmašuju s njim povezane rizike u svim ispitanim dobnim grupama te je preporučilo davanje odobrenja za stavljanje cjepiva u promet.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pandemic Influenza Vaccine H5N1 Baxter AG, including the appropriate precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku, za cjepivo protiv pandemijske influence H5N1 Baxter AG uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
The viruses used in Pandemic Influenza Vaccine H5N1 Baxter AG are grown in mammal cells (‘vero cells'), unlike those in some other flu vaccines, which are grown in hen's eggs. 
Virusi korišteni u cjepivu protiv pandemijske influence H5N1 Baxter AG uzgajaju se u stanicama sisavaca („vero stanicama”) za razliku od određenih drugih cjepiva protiv gripe, koji se uzgajaju u kokošjim stanicama.
The study looked at the ability of two 7.5 microgram doses of the vaccine, given 21 days apart, to trigger the production of antibodies (‘immunogenicity').The main measures of effectiveness were the levels of antibodies against the flu virus in the blood before vaccination, on the day of the second injection (day 21), and 21 days after the second vaccination (day 42). 
Glavna mjera djelotvornosti su bile razine protutijela protiv virusa gripe u krvi prije cijepljenja, na dan druge injekcije (dan 21.) i 21 dan nakon drugog cijepljenja (dan 42.).
Pandemic Influenza Vaccine H5N1 Baxter AG has been authorised under ‘Exceptional Circumstances'. 
Cjepivo protiv pandemijske influence H5N1 Baxter AG odobreno je u „iznimnim okolnostima”.
This means that, because the vaccine is a mock up and does not yet contain the strain of flu virus that is causing a pandemic, it has not been possible to obtain full information about the final pandemic vaccine. 
Tome je razlog nemogućnost dobivanja potpunih informacija o konačnom cjepivu protiv pandemije zato što je cjepivo razvijeno koristeći reprezentativan uzorak te još uvijek ne sadrži soj virusa gripe koji uzrokuje pandemiju.